Responding to the Kentucky senator's statement, the F.D.A. said that it was reversing its earlier decision but would refer Paul for further clinical study.
Full story here.
Originally published 2021-08-23 10:36:55 — www.newyorker.com
Visited 1 times, 1 visit(s) today
